2026年10月12日，谷歌详细介绍了其在疾病研究与生物制药工具领域的多项人工智能项目。这些项目涵盖细胞研究、临床诊疗工具开发以及诊断辅助技术。
Google Details AI Initiatives in Disease Research and Biopharma Tools On October 12, 2026, Google outlined its ongoing artificial intelligence health initiatives spanning cellular discovery, clinical tools, and diagnostic support.
谷歌还重点介绍了与各大学术及医疗机构的合作情况，这些合作主要依托AlphaFold、AlphaGenome Atlas、DeepVariant和DeepSomatic等先进模型来开展。
The company highlighted collaborations with academic and medical institutions using models such as AlphaFold, AlphaGenome Atlas, DeepVariant, and DeepSomatic.
目前取得的成果包括发现了可用于治疗恰加斯病的潜在药物、将乳腺X光影像分析的工作量降低了40%且能更精准地发现早期癌症，以及借助AlphaProtein Novo技术成功设计出新型合成酶。
Key achievements noted include identifying repurposed drug candidates for Chagas disease, reducing mammography reading workloads by up to 40% while identifying interval cancers, and designing synthetic enzymes via AlphaProtein Novo.
此外，谷歌旗下的公益机构Google.org宣布，2026年将投入超过6000万美元，用于支持全球范围内致力于将先进人工智能技术应用于生物医学与疾病研究的各类组织。
Additionally, Google announced that its philanthropic arm, Google.org, committed more than $60 million in 2026 to support global organizations applying advanced AI models to biomedical and disease research.